MX2023012363A - Composiciones de anticuerpos anti-tslp y usos de las mismas. - Google Patents

Composiciones de anticuerpos anti-tslp y usos de las mismas.

Info

Publication number
MX2023012363A
MX2023012363A MX2023012363A MX2023012363A MX2023012363A MX 2023012363 A MX2023012363 A MX 2023012363A MX 2023012363 A MX2023012363 A MX 2023012363A MX 2023012363 A MX2023012363 A MX 2023012363A MX 2023012363 A MX2023012363 A MX 2023012363A
Authority
MX
Mexico
Prior art keywords
antibody compositions
tslp antibody
tslp
compositions
antibody
Prior art date
Application number
MX2023012363A
Other languages
English (en)
Inventor
Hao Zhang
Dong Xiang
Marisa Joubert
Alla Polozova
Kelly Fitzpatrick
Kristin Abrams
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2023012363A publication Critical patent/MX2023012363A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente solicitud se refiere, en general, a composiciones que comprenden el anticuerpo anti-TSLP tezepelumab y derivados del mismo que tienen atributos de calidad del anticuerpo.
MX2023012363A 2021-04-23 2022-04-22 Composiciones de anticuerpos anti-tslp y usos de las mismas. MX2023012363A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163178938P 2021-04-23 2021-04-23
PCT/US2022/025994 WO2022226339A1 (en) 2021-04-23 2022-04-22 Anti-tslp antibody compositions and uses thereof

Publications (1)

Publication Number Publication Date
MX2023012363A true MX2023012363A (es) 2023-11-01

Family

ID=81597810

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023012363A MX2023012363A (es) 2021-04-23 2022-04-22 Composiciones de anticuerpos anti-tslp y usos de las mismas.

Country Status (18)

Country Link
US (1) US20240190951A1 (es)
EP (1) EP4326766A1 (es)
JP (1) JP2024517418A (es)
KR (1) KR20240000537A (es)
CN (1) CN117203233A (es)
AR (1) AR125408A1 (es)
AU (1) AU2022262421A1 (es)
BR (1) BR112023021867A2 (es)
CA (1) CA3216655A1 (es)
CL (1) CL2023003155A1 (es)
CO (1) CO2023014181A2 (es)
CR (1) CR20230531A (es)
IL (1) IL307540A (es)
MX (1) MX2023012363A (es)
PE (1) PE20240068A1 (es)
TW (1) TW202308690A (es)
UY (1) UY39736A (es)
WO (1) WO2022226339A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12110324B2 (en) 2022-07-22 2024-10-08 Flagship Pioneering Innovations Vi, Llc Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP)
WO2024163978A2 (en) 2023-02-02 2024-08-08 Medimmune, Llc Treatment of chronic rhinosinusitis with anti-tslp antibody

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
WO1990003430A1 (en) 1988-09-23 1990-04-05 Cetus Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE69127627T2 (de) 1990-08-29 1998-02-19 Genpharm Int Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
US8359965B2 (en) 2007-09-17 2013-01-29 Oxford J Craig Apparatus and method for broad spectrum radiation attenuation
TW201201840A (en) 2010-07-15 2012-01-16 Hoffmann La Roche Antibodies specifically binding to human TSLPR and methods of use
AT510032B1 (de) 2010-11-30 2012-01-15 Steiner Erwin Ing Montageeinrichtung für fassadenelemente
US9100245B1 (en) 2012-02-08 2015-08-04 Amazon Technologies, Inc. Identifying protected media files
US20140227250A1 (en) * 2012-08-23 2014-08-14 Merck Sharp & Dohme Corp. Stable formulations of antibodies to tslp
US9306926B2 (en) 2013-03-15 2016-04-05 Brian A. Truong User authentication using unique hidden identifiers
CN106170554B (zh) 2014-01-29 2021-08-17 美国安进公司 过表达n-糖基化途径调节基因以调节重组蛋白的糖基化
JP2018509153A (ja) * 2015-03-11 2018-04-05 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｔｓｌｐ結合タンパク質
JOP20190243A1 (ar) 2017-04-12 2019-10-13 Medimmune Llc علاج الربو بجسم مضاد لـ tslp
CN110709121B (zh) 2017-06-08 2022-06-24 安进公司 扭矩驱动式药物递送装置
MA49757A (fr) * 2017-08-01 2020-06-10 Amgen Inc Systèmes et procédés de préparation en temps réel d'un échantillon de polypeptide pour analyse par spectrométrie de masse
JP7247174B2 (ja) 2017-11-10 2023-03-28 アムジエン・インコーポレーテツド 薬物送達デバイスのプランジャ
US20210041453A1 (en) 2018-03-13 2021-02-11 Amgen Inc. Methods for the preparation of trypsin-resistant polypeptides for mass spectrometric analysis
WO2020081479A1 (en) 2018-10-15 2020-04-23 Amgen Inc. Drug delivery device having damping mechanism
EP3866889A1 (en) 2018-10-15 2021-08-25 Amgen Inc. Platform assembly process for drug delivery device
WO2020223422A1 (en) 2019-04-30 2020-11-05 Amgen Inc. Data-driven predictive modeling for cell line selection in biopharmaceutical production
MA56121A (fr) 2019-06-05 2022-04-13 Amgen Inc Procédés d'identification d'attributs de protéines thérapeutiques

Also Published As

Publication number Publication date
CO2023014181A2 (es) 2023-10-30
BR112023021867A2 (pt) 2023-12-19
CA3216655A1 (en) 2022-10-27
CL2023003155A1 (es) 2024-04-19
UY39736A (es) 2022-10-31
JP2024517418A (ja) 2024-04-22
CR20230531A (es) 2024-01-08
US20240190951A1 (en) 2024-06-13
TW202308690A (zh) 2023-03-01
EP4326766A1 (en) 2024-02-28
CN117203233A (zh) 2023-12-08
AR125408A1 (es) 2023-07-12
WO2022226339A1 (en) 2022-10-27
PE20240068A1 (es) 2024-01-11
IL307540A (en) 2023-12-01
AU2022262421A1 (en) 2023-10-19
KR20240000537A (ko) 2024-01-02
WO2022226339A9 (en) 2023-08-24

Similar Documents

Publication Publication Date Title
AU2016320806A8 (en) Stable inoculant compositions and methods for producing same
EP4233843A3 (en) Antibody compositions
MX2021006681A (es) Anticuerpos anti-claudina y usos de los mismos.
MX2023012363A (es) Composiciones de anticuerpos anti-tslp y usos de las mismas.
RS20050769A (en) Derivatives of 2-acylamino-4- phenylthiazole,preparation method thereof and application of same in therapeutics
MY190627A (en) Anti-vegf protein compositions and methods for producing the same
MX2020013421A (es) Composiciones de dióxido de silicio de carbono poroso biogénico, métodos de elaboracion y uso de estas.
WO2022226342A3 (en) Modified anti-tslp antibodies
MX2021015846A (es) Derivados de antraciclina.
MX2022001449A (es) Compuestos de aminoesterol humano ent-03, composiciones relacionadas que comprenden los mismos y metodos para usar los mismos.
MX2021005956A (es) Composiciones biologicas secas y metodos de las mismas.
MX2022007799A (es) Hojas expansibles activadas por tension.
MX2021008983A (es) Atributos de aflibercept y metodos de caracterizacion y modificacion de los mismos.
WO2020235974A3 (ko) 단일염기 치환 단백질 및 이를 포함하는 조성물
MX2022013840A (es) Polipéptidos de unión a pd-1 canina y usos de los mismos.
WO2021076574A3 (en) Fn3 domain-sirna conjugates and uses thereof
MX2023009724A (es) Sustitucion de amoniaco en productos para alterar el cabello.
MX2023014154A (es) Anticuerpos anti-ccr8.
IL310535A (en) Anti-GDF15 antibodies, compositions and uses thereof
MX2023001160A (es) Composicion farmaceutica del anticuerpo anti-pd-1 y uso del mismo.
WO2022067233A3 (en) Canine antibody variants
WO2022238590A3 (en) Piroctone particles for use in cosmetic compositions
WO2020123070A3 (en) Emm-41 composition, methods of making and uses thereof
MX2024002913A (es) Anticuerpos anti-siglec-6 y metodos de uso de los mismos.
MX2023007302A (es) Anticuerpos contra la integrina alfa 11 beta 1.